12:00 AM
Dec 06, 2010
 |  BioCentury  |  Finance

Dubious about prophylaxis

Fund managers unenthusiastic about prophylactic use of Gilead's Truvada in HIV

Buysiders showed little enthusiasm for data showing efficacy for Truvada emtricitabine/tenofovir as a prophylaxis for HIV. But at least one sellside analyst is throwing out blockbuster market projections.

For its part, Gilead Sciences Inc. (NASDAQ:GILD), which markets the fixed-dose combination of two nucleoside analog reverse transcriptase inhibitors, last week told the Piper Jaffray Healthcare Conference in New York that it is working with regulatory authorities, including FDA and EMA, to add HIV prophylaxis to Truvada's label.

President and COO John Milligan noted that in addition to the newly reported study, more than 20,000 volunteers are being dosed with Truvada for this indication, with additional data forthcoming.

In the Phase III iPrEx HIV prophylaxis study in 2,499 HIV-seronegative men who have sex with men, Truvada met the primary...

Read the full 622 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >